Physician profile
James P Pacelli
NPI 1144216524
$1,847.53
in general payments reported to CMS, 2019-2025
17 companies · $428 in 2025
The $428 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $179 · 2023: $521 · 2024: $720 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,668.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $339.56 | 2022-2025 | Tysabri, Vumerity, Spinraza |
| Lundbeck LLC | $291.38 | 2023-2025 | Vyepti, Rexulti |
| Abbvie INC. | $234.10 | 2022-2025 | |
| Pfizer INC. | $209.68 | 2023-2024 | |
| Acadia Pharmaceuticals INC | $111.14 | 2024-2025 | Nuplazid |
| Ucb, INC. | $83.51 | 2023-2025 | Briviact |
| Argenx US, INC. | $77.97 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $71.93 | 2022-2024 | Reyvow, Emgality, Kisunla |
| Neurelis, INC. | $67.26 | 2022-2024 | Valtoco |
| Neurocrine Biosciences, INC. | $65.84 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $62.39 | 2024-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $57.68 | 2022 | |
| Tanabe Pharma America, INC. | $51.26 | 2023-2024 | |
| Genentech USA, INC. | $39.31 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Amneal Pharmaceuticals LLC | $32.42 | 2024 | Rytary, Crexont |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $28.80 | 2024 | Austedo Xr |
| Mallinckrodt Hospital Products INC. | $23.30 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pacelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.